NasdaqCM:OVIDBiotechs
Ovid Therapeutics (OVID) Is Up 6.4% After Positive Phase 1 Results for Drug-Resistant Epilepsy Candidate
Ovid Therapeutics recently announced positive topline results from its Phase 1 study of OV329, a next-generation GABA-aminotransferase inhibitor targeting drug-resistant epilepsies, demonstrating significant GABAergic inhibition and strong safety outcomes in 68 healthy volunteers.
This clinical milestone signals potential advancement in the treatment of drug-resistant epilepsies and attracted new institutional investors through a substantial private placement.
We'll explore how OV329’s early...